Influence of Premedication Protocols for Neonatal Endotracheal Intubation on Cerebral Oxygenation

NCT ID: NCT01427985

Last Updated: 2016-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine the influence of premedication drugs Atropin, Fentanyl and Mivacurium and of endotracheal intubation on cerebral oxygenation and cardiac output in term and preterm newborn infants. Two different protocols of premedication are compared.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Influence of the following procedures will be examined:

* Application of Atropin
* Application of Fentanyl
* Application of Mivacurium
* possible desaturation and / or bradycardia during intubation attempts
* restoration of arterial oxygen saturation and / or heart rate after succesful intubation

We aim to examine the change of the following parameters by the use of electrical cardiometry:

* stroke volume
* cardiac output

We compare two different premedication protocols and we evaluate the impact of these protocol on the time needed for intubation and on intubation difficulties .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Newborn Preterm Intubation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Relaxation followed by analgosedation

Give Atropin, then Mivacurium, immediately followed by Fentanyl

Group Type EXPERIMENTAL

Atropine, Fentanyl, Mivacurium

Intervention Type DRUG

1. Atropin 10µg/kg
2. Mivacurium 200µg/kg immediately followed by
3. Fentanyl 2µg/kg

Analgosedation followed by Relaxation

Give atropin, then Fentanyl, then Mivacurium

Group Type ACTIVE_COMPARATOR

Atropine, Fentanyl, Mivacurium

Intervention Type DRUG

1. Atropin 10µg/kg
2. Fentanyl 2µg/kg, repeat max. two times
3. Mivacurium 200µg/kg

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atropine, Fentanyl, Mivacurium

1. Atropin 10µg/kg
2. Mivacurium 200µg/kg immediately followed by
3. Fentanyl 2µg/kg

Intervention Type DRUG

Atropine, Fentanyl, Mivacurium

1. Atropin 10µg/kg
2. Fentanyl 2µg/kg, repeat max. two times
3. Mivacurium 200µg/kg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* newborn infant below 44 weeks postmenstrual age
* indication for elective or semi-elective endotracheal Intubation
* parental informed consent

Exclusion Criteria

* emergency intubation
Maximum Eligible Age

44 Weeks

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Ulm

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Manuel Schmid

Dr. med.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manuel B Schmid, Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University of Ulm

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center

Ulm, Baden-Wurttemberg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ULMNEONIRS02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.